Hanmi Fine Chemical launches ‘high-tech CDMO’ business

The CDMO business began, such as mRNA vaccine raw materials · peptides

KRW 10 billion was invested in the expansion of the Hanmi Fine Chemical facility

SEOUL, South Korea, May 22, 2022 / PRNewswire / – is a subsidiary of Hanmi Fine Chemical (hereinafter Hanmi FC). Hanmi Pharmacy Group Specializing in the development and manufacturing of APIs (Pharmaceutical Active Ingredients), it is accelerating a new business, expanding its expertise from ongoing APIs to “high-tech CDMO” services.

As a result of the COVID-19 pandemic, there has been an increase in the global demand for high-level synthetic biopharmaceutical raw materials, such as those used in mRNA vaccines, including lipid nanoparticles (LNPs), nucleotides, coating materials, and polyethylene. glycol (PEG) derivatives and peptides. Therefore, on May 23, 2022, Hanmi FC (CEO Chang Young-kil) announced that it would launch its business areas to include CDMO projects in key areas.

Processing of raw material production at the Hanmi FC manufacturing line.

To this end, Hanmi FC will invest around KRW 10 billion to build “high-tech CDMO” facilities. Last year, Hanmi FC was selected by the Korean government to carry out a project to expand COVID-19 vaccine and raw material production facilities, and received 1.6 billion KRW for these efforts. In addition, the company plans to renovate these facilities even further, with a total of KRW 8 billion of its funds.

Hanmi Fine Chemicals has gained global competitiveness in the CDMO industry by participating in Hanmi Pharmaceutical’s R&D of biologics and anti-cancer drugs and successfully passing GMP inspections in major countries with advanced pharmaceutical sectors such as Germany, the United Kingdom, Japan and the US FDA. .

In addition, Hanmi FC is currently responsible for the development and production of new innovative medicines at Hanmi Pharmaceutical, including Belvarafenib (in collaboration with Gentech), MKI (in collaboration with Aptose) and Poziotinib (in collaboration with Spectrum). It is also developing and producing raw materials TRAVELSTriple Agonist, TRAVELSDouble agonist, TRAVELSGlucagon analog, and TRAVELSGLP-2 Analog, Biological Basics from Hanmi Pharmaceutical.

Based on this competitiveness, Hanmi FC is currently conducting 10 billion KRW CDMO preclinical and clinical projects with 10 domestic and foreign companies, and is expected to establish partnerships with even more companies in the second half of 2022.

In addition, to expand the overall performance of its CDMO business, Hanmi FC is actively participating in various domestic and foreign exhibitions. In May, TIDES participated in US (9-12, Boston, USA), BIO KOREA (11-13, Seoul) and InformEx (CPhI North America, 17-19, Philadelphia, USA). Hanmi FC will take part in the BIO International Convention to be held in San Diego, USA from June 13-16. Finally, at the end of this year, Hanmi FC intends to go to TIDES Europe from 15 to 18 November. Vienan, Austrian.

Hanmi FC CEO Chang Young-kil stressed that the company has sufficient global competitiveness and the ability to rapidly develop materials that require advanced synthetic technology, such as mRNA raw materials, to be at the forefront in Korea.

[Reference Materials] About Hanmi Fine Chemical

Founded in 1984, Hanmi FC is a company specializing in APIs. In 1993, he built a large-scale Korean raw material synthesis GMP plant at Sihwa Industrial Complex in Gyeonggi-do.

The quality of Hanmi FC’s cephalosporin products is recognized not only in Korea, but also in developed markets such as the USA and Europe. In 2006, Hanmi FC successfully passed the US FDA inspection in the sterile raw materials sector. In addition, it has demonstrated its global competitiveness through the approval of GMP inspections by major advanced pharmaceutical countries such as Germany, the United Kingdom and Japan. It has also demonstrated practical capabilities for conducting a global CDMO in a number of areas, such as the mass production of existing APIs and the operation of GMP.

Recently, Hanmi FC has been able to synthesize and develop the essential raw materials for the manufacture of mRNA vaccines and plans to expand its facilities for mass production. These include excellent human resources from major domestic and foreign pharmaceutical research centers, such as the Hanmi Pharmaceutical Research Center, which is responsible for the company’s R&D. Hanmi FC currently exports its products to more than 30 countries around the world.

Cision View original multimedia content for download: https://www.prnewswire.com/news-releases/hanmi-fine-chemical-launches-high-tech-cdmo-business-301552577.html

SOURCE Hanmi Pharmaceutical

Business Codes: Korea: 128940


Leave a Comment